Skip to main content
main-content

Oncology news

23-05-2017 | Head and neck cancer | Highlight | Article

Editor's pick

Recommendation against routine thyroid cancer screening retained

In a statement published in JAMA, the US Preventive Services Task Force upholds its 1996 recommendation against screening for thyroid cancer among asymptomatic adults.

Source:

JAMA 2017; 317: 1840–1841, 1882–1887, 1888–1903, JAMA Otolaryngol Head Neck Surg 2017; Advance online publication, JAMA Surg 2017; Advance online publication

26-05-2017 | Non-small-cell lung cancer | News | Article

Alectinib outperforms crizotinib in Japanese patients with ALK-rearranged NSCLC

Among Japanese patients with advanced non-small-cell lung cancer harboring anaplastic lymphoma kinase translocations, progression-free survival is significantly longer with alectinib than crizotinib, shows a head-to-head phase III trial.

Source:

Lancet 2017; Advance online publication

25-05-2017 | Non-small-cell lung cancer | News | Article

approvalsWatch

Pembrolizumab receives agnostic approval for MSI-H/dMMR tumors

Click through to read more on these announcements

24-05-2017 | Gynaecological cancer | News | Article

Bevacizumab benefits ovarian cancer patients irrespective of timing

Patients with platinum-resistant ovarian cancer gain significant survival benefit from treatment with bevacizumab, regardless of whether its given with or after chemotherapy, an exploratory analysis of AURELIA study data show.

Source:

Ann Oncol 2017; Advance online publication

22-05-2017 | Oncology | News | Article

Targeting mitochondrial metabolism shows promise in pancreatic cancer

Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.

Source:

Lancet Oncol 2017; Advance online publication

Beta Blocker Use Linked To Advanced HER2-Negative Breast Cancer PFS

Exploratory analysis of breast cancer trial participants supports the hypothesis that beta blocker use may influence progression-free survival of some patient subgroups

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology

ESMO 2016 coverage

medwireNews@ESMO2016

medwireNews brings you news and conference reports from the ESMO 2016 Congress, held in Copenhagen, Denmark.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits